OmniActive’s Supa Facility Passes FDA Audit


OmniActive Health Technologies’ Supa, India facility is its fourth to successfully go through the FDA CFR110 cGMP audit, joining its facilities in Oros, Pune and Talwar, India.
 
“OmniActive consistently strives to meet the highest quality and regulatory controls by continuously optimizing our operations and facilities,” stated Chaitanya Desai, COO. “Our efforts in meeting and exceeding the world’s strictest standards serve as the foundation of our achievements, as recognized by the FDA.” 
 
OmniActive said it ensures that all personnel are fully trained in several aspects of operational excellence and quality control standards, and its facilities are certified cGMP and ISO9005:22000. In addition, as a responsible supplier, OmniActive’s ingredients are produced through effective, efficient and sustainable operations.
 
“We take great pride in our efforts, and being recognized for doing so under rigorous analysis by the U.S. FDA further solidifies our dedication to deliver the industry with premium, innovative ingredients,” said Lynda Doyle, vice president, global marketing, OmniActive.